BACKGROUND: Rituximab may improve transplant outcomes but may delay immunologic recovery. PATIENTS AND METHODS: Seventy-seven patients with low-grade or mantle cell lymphoma received autologous stem-cell transplantation (ASCT) on a phase II study. Rituximab 375 mg/m(2) was administered 3 days before mobilization-dose cyclophosphamide, then weekly for four doses after count recovery from ASCT. Immune reconstitution was assessed. RESULTS: Sixty percent of transplants occurred in first remission. Actuarial event-free survival (EFS) and overall survival (OS) were 60% and 73%, respectively, at 5 years, with 7.2-year median follow-up for OS in surviving patients. Median EFS was 8.3 years. Older age and transformed lymphomas were independently associated with inferior EFS, whereas day 60 lymphocyte counts did not predict EFS or late infections. Early and late transplant-related mortality was 1% and 8%, with secondary leukemia in two patients. B-cell counts recovered by 1-2 years; however, the median IgG level remained low at 2 years. Late-onset idiopathic neutropenia, generally inconsequential, was noted in 43%. CONCLUSION: ASCT with rituximab can produce durable remissions on follow-up out to 10 years. Major infections do not appear to be significantly increased or to be predicted by immune monitoring.
BACKGROUND:Rituximab may improve transplant outcomes but may delay immunologic recovery. PATIENTS AND METHODS: Seventy-seven patients with low-grade or mantle cell lymphoma received autologous stem-cell transplantation (ASCT) on a phase II study. Rituximab 375 mg/m(2) was administered 3 days before mobilization-dose cyclophosphamide, then weekly for four doses after count recovery from ASCT. Immune reconstitution was assessed. RESULTS: Sixty percent of transplants occurred in first remission. Actuarial event-free survival (EFS) and overall survival (OS) were 60% and 73%, respectively, at 5 years, with 7.2-year median follow-up for OS in surviving patients. Median EFS was 8.3 years. Older age and transformed lymphomas were independently associated with inferior EFS, whereas day 60 lymphocyte counts did not predict EFS or late infections. Early and late transplant-related mortality was 1% and 8%, with secondary leukemia in two patients. B-cell counts recovered by 1-2 years; however, the median IgG level remained low at 2 years. Late-onset idiopathic neutropenia, generally inconsequential, was noted in 43%. CONCLUSION: ASCT with rituximab can produce durable remissions on follow-up out to 10 years. Major infections do not appear to be significantly increased or to be predicted by immune monitoring.
Authors: S H Lim; Y Zhang; Z Wang; W V Esler; D Beggs; B Pruitt; P Hancock; M Townsend Journal: Bone Marrow Transplant Date: 2005-01 Impact factor: 5.483
Authors: Yvette L Kasamon; Richard J Jones; Louis F Diehl; Hassan Nayer; Michael J Borowitz; Elizabeth Garrett-Mayer; Richard F Ambinder; Ross A Abrams; Zhe Zhang; Ian W Flinn Journal: Biol Blood Marrow Transplant Date: 2005-01 Impact factor: 5.742
Authors: W Brugger; J Hirsch; F Grünebach; R Repp; P Brossart; W Vogel; H-G Kopp; M G Manz; M Bitzer; G Schlimok; M Kaufmann; A Ganser; K Fehnle; M Gramatzki; L Kanz Journal: Ann Oncol Date: 2004-11 Impact factor: 32.976
Authors: L B Grochow; R J Jones; R B Brundrett; H G Braine; T L Chen; R Saral; G W Santos; O M Colvin Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333
Authors: Harry C Schouten; Wendi Qian; Stein Kvaloy; Adolfo Porcellini; Hans Hagberg; Hans Erik Johnsen; Jeanette K Doorduijn; Matthew R Sydes; Gunnar Kvalheim Journal: J Clin Oncol Date: 2003-09-29 Impact factor: 44.544
Authors: J G Gribben; A S Freedman; D Neuberg; D C Roy; K W Blake; S D Woo; M L Grossbard; S N Rabinowe; F Coral; G J Freeman Journal: N Engl J Med Date: 1991-11-28 Impact factor: 91.245
Authors: Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Dennis A Gastineau; Mark R Litzow; Jeffrey L Winters; Svetomir N Markovic Journal: Biol Blood Marrow Transplant Date: 2008-07 Impact factor: 5.742
Authors: S Montoto; C Canals; A Z S Rohatiner; G Taghipour; A Sureda; N Schmitz; C Gisselbrecht; L Fouillard; N Milpied; C Haioun; S Slavin; E Conde; C Fruchart; A Ferrant; V Leblond; H Tilly; T A Lister; A H Goldstone Journal: Leukemia Date: 2007-07-19 Impact factor: 11.528
Authors: John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana Journal: Blood Adv Date: 2021-01-12
Authors: Yvette L Kasamon; Richard J Jones; Christopher D Gocke; Amanda L Blackford; Eric J Seifter; Janice M Davis-Sproul; Steven D Gore; Richard F Ambinder Journal: Biol Blood Marrow Transplant Date: 2010-07-22 Impact factor: 5.742
Authors: Margaret M Showel; Robert A Brodsky; Hua-Ling Tsai; Katlyn M Briel; Jeanne Kowalski; Constance A Griffin; Richard J Jones Journal: Biol Blood Marrow Transplant Date: 2014-04-13 Impact factor: 5.742
Authors: G Zugmaier; M S Topp; S Alekar; A Viardot; H-A Horst; S Neumann; M Stelljes; R C Bargou; M Goebeler; D Wessiepe; E Degenhard; N Gökbuget; M Klinger Journal: Blood Cancer J Date: 2014-09-05 Impact factor: 11.037